M
Manuela Machado
Publications - 4
Citations - 1368
Manuela Machado is an academic researcher. The author has contributed to research in topics: Pembrolizumab & Cancer. The author has an hindex of 3, co-authored 3 publications receiving 889 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Journal ArticleDOI
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
Charles S. Fuchs,Toshihiko Doi,Raymond Woo-Jun Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean-Philippe Metges,Marcelo Garrido,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Yung-Jue Bang,Jiangdian Wang,Minori Koshiji,Rita P. Dalal,Harry H. Yoon +19 more
TL;DR: A global, multicohort, phase 2 study of pembro in pts with advanced gastric or gastroesophageal junction (G/GEJ) cancer with promising antitumor activity and manageable safety and primary end points: ORR, safety, and tolerability.
Journal ArticleDOI
PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
TL;DR: A systematic review and meta-analysis of the evidence on programmed cell death protein ligand 1 (PD-L1) in Epstein-Barr virus associated gastric cancer (EBVaGC) and the expression rate of PD-L 1 among this subtype of Gastric Cancer (GC) is presented in this article .
Journal ArticleDOI
KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis.
Kei Muro,Charles S. Fuchs,Raymond Woo-Jun Jang,Taroh Satoh,Manuela Machado,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean-Philippe Metges,Marcelo Garrido,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Yung-Jue Bang,Jianxin Lin,Jia Lu,Harry H. Yoon,Toshihiko Doi +18 more
TL;DR: The US FDA approved pembro for treating pts with recurrent locally advanced or metastatic G/GEJ adenocarcinoma, whose disease has progressed on or after ≥2 prior therapies and who...